World Congress on Gastrointestinal Cancer



		Email this link to a friend. U.S. residents, click here to download a printable version of the latest announcement. Outside the U.S., click here for printable version of the latest announcement.



		The following companies have provided unrestricted educational grants in support of this conference:
	FOUNDING PLATINUM SILVER CONTRIBUTOR



		Several support options are available to companies interested in supporting this conference. For more information, please contact Anne Rojas at +1 (770) 200-7025, or by email at a.rojas@imedex.com

16 - 19 JUNE 2004
World Congress on Gastrointestinal Cancer
Barcelona, Spain

Chairs:
Mario Dicato, MD
Luxembourg Medical Center
Luxembourg, Luxembourg

Eric Van Cutsem, MD, PhD
University Hospital Gasthuisberg
Leuven, Belgium

Click here to register for this program


		CONTENTS · Scientific Committee · Faculty · Scientific Agenda · Continuing Medical Education · General Information · Hotel Accommodations

S C I E N T I F I C C O M M I T T E E

Nadir Arber, MD
Ichilov Hospital
Tel Aviv, Israel

David Cunningham, MD
The Royal Marsden Hospital
Surrey, United Kingdom

Eduardo Diaz-Rubio, MD
San Carlos Hospital Clinic
Madrid, Spain

Mario Dicato, MD
Chairman
Luxembourg Medical Center
Luxembourg, Luxembourg

Bengt Glimelius, MD
University of Uppsala
Uppsala, Sweden

Richard M. Goldberg, MD
University of North Carolina
at Chapel Hill
Chapel Hill, North Carolina, United States

Daniel G. Haller, MD
University of Pennsylvania
Cancer Center
Philadelphia, Pennsylvania, United States

Karin Haustermans, MD, PhD
University Hospital Gasthuisberg
Leuven, Belgium

Patrick G. Johnston, MD, PhD
The Queen's University of Belfast
Belfast, Ireland

Yoon-Koo Kang, MD, PhD
Asian Medical Center
University of Ulsan
Seoul, Korea

Roberto Labianca, MD
Ospedale Riuniti
Bergamo, Italy

John S. Macdonald, MD
St. Vincent’s Comprehensive Cancer Center
New York, New York, United States

Bruce D. Minsky, MD
Memorial Sloan-Kettering
Cancer Center
New York, New York, United States

Bernard Nordlinger, MD
Hôpital Ambroise Paré
Boulogne, France

Arnaud D. Roth, MD
Geneva University Hospital
Geneva, Switzerland

Philippe Rougier, MD
Hôpital Ambroise Paré
Boulogne, France

Werner Scheithauer, MD
Vienna University Hospital
Vienna, Austria

Hans-Joachim Schmoll, MD
Martin Luther Universität
Halle, Germany

Eric Van Cutsem, MD, PhD
Chairman
University Hospital Gasthuisberg
Leuven, Belgium

Cornelis J.H. van de Velde, MD, PhD
Leiden University Medical Center
Leiden, The Netherlands

Jacques Wils, MD
Honorary Member
Roermond, The Netherlands

John R. Zalcberg, MD
Peter MacCallum Cancer Institute
East Melbourne, Victoria, Australia

F A C U L T Y

James L. Abbruzzese, MD
MD Anderson Cancer Center
Houston, Texas, United States

Nadir Arber, MD
Ichilov Hospital
Tel Aviv, Israel

Wendy P. Atkin, MPH, PhD
St Mark's Hospital Northwick Park
Middlesex, United Kingdom

Regina Beets-Tan, MD, PhD
University Hospital Maastricht
Maastricht, The Netherlands

Al B. Benson III, MD
Northwestern University
Chicago, Illinois, United States

Charles D. Blanke, MD
Oregon Health Sciences University
Portland, Oregon, United States

Jean-François Bosset, MD
Besançon University
Besançon, France

Jordi Bruix, MD
Barcelona Clinic
Barcelona, Spain

Stefano Cascinu, MD
Azienda Ospedaliera Umberto I
Ancona, Italy

David Cunningham, MD
The Royal Marsden Hospital
Surrey, United Kingdom

Thierry de Baère, MD
Institut Gustave Roussy
Paris, France

Aimery de Gramont, MD
Hôpital Saint Antoine
Paris, France

Valerio Di Carlo, MD
Università Vita-Salute San Raffaele
Milan, Italy

Eduardo Díaz-Rubio, MD
San Carlos Hospital Clinic
Madrid, Spain

Mario Dicato, MD
Luxembourg Medical Center
Luxembourg, Luxembourg

Michel Ducreux, MD, PhD
Institut Gustave Roussy
Paris, France

Dominique Elias, MD
Institut Gustave Roussy
Paris, France

Patrick Flamen, MD, PhD
Institut Jules Bordet
Brussels, Belgium

Marc Giovannini, MD
Institut Paoli-Calmettes
Marseille, France

Bengt Glimelius, MD
University of Uppsala
Uppsala, Sweden

Robert Glynne-Jones, MD
Mount Vernon Hospital
Middlesex, United Kingdom

Richard M. Goldberg, MD
University of North Carolina
Chapel Hill, North Carolina,
United States

Dirk J. Gouma, MD
Academisch Medisch Centrum
Amsterdam, The Netherlands

Daniel G. Haller, MD
University of Pennsylvania
Cancer Center
Philadelphia, Pennsylvania,
United States

Karin Haustermans, MD, PhD
University Hospital Gasthuisberg
Leuven, Belgium

Paulo M. Hoff, MD
MD Anderson Cancer Center
Houston, Texas, United States

Patrick G. Johnston, MD, PhD
The Queen’s University of Belfast
Belfast, Northern Ireland

Yoon-Koo Kang, MD, PhD
Asian Medical Center
University of Ulsan
Seoul, Korea

David J. Kerr, CBE, MD, FRCP
Radcliffe Infirmary
Oxford, United Kingdom

Claus-Henning Köhne, MD, PhD
University Clinic Dresden
Dresden, Germany

Roberto Labianca, MD
Ospedale Riuniti
Bergamo, Italy

Andrea Laghi, MD
University La Sapienza
Rome, Italy

Toni Lerut, MD
University Hospital Gasthuisberg
Leuven, Belgium

Manfred P. Lutz, MD
Caritas Klinik
Saarbrücken, Germany

John S. Macdonald, MD
St. Vincent's Comprehensive
Cancer Center
New York, New York, United States

Markku Miettinen, MD, PhD
Armed Forces Institute of Pathology
Washington, District of Columbia, United States

Bruce D. Minsky, MD
Memorial Sloan-Kettering Cancer Center
New York, New York, United States

Bernard Nordlinger, MD
Hôpital Ambroise Paré
Boulogne, France

Lars Pahlman, MD, PhD
University Hospital
Uppsala, Sweden

Arnaud D. Roth, MD
Geneva University Hospital
Geneva, Switzerland

Phillipe Rougier, MD
Hôpital Ambroise Paré
Boulogne, France

Werner Scheithauer, MD
Vienna University Hospital
Vienna, Austria

Hans-Joachim Schmoll, MD, PhD
Martin Luther Universität
Halle, Germany

David Sebag-Montefiore, MD
Leeds Cancer Centre
Leeds, United Kingdom

Sigrid Stroobants, MD, PhD
Catholic University Leuven
Leuven, Belgium

Josep Tabernero, MD
Hospital Vall d’Hebron
Barcelona, Spain

Sabine Tejpar, MD, PhD
University Hospital Gasthuisberg
Leuven, Belgium

Margaret A. Tempero, MD
University of California San Francisco
San Francisco, California, United States

Joel E. Tepper, MD
University of North Carolina
at Chapel Hill
Chapel Hill, North Carolina,
United States

Vincenzo Valentini, MD
Università Cattolica del Sacro Cuore
Rome, Italy

Eric Van Cutsem, MD, PhD
University Hospital Gasthuisberg
Leuven, Belgium

Cornelis J.H. van de Velde, MD, PhD
Leiden University Medical Center
Leiden, The Netherlands

Jean-Luc Van Laethem, MD, PhD
Hôspital Erasme
Brussels, Belgium

Bertram Wiedenmann, MD
Charité Hospital
Berlin, Germany

Hans-Jochen Wilke, MD
Kliniken-Essen-Mitte
Essen, Germany

John R. Zalcberg, MD
Peter MacCallum Cancer Institute
East Melbourne, Victoria, Australia

S C I E N T I F I C A G E N D A

Wednesday, 16 June 2004
14:00	Expert discussion: Surveillance and follow-up of colon cancer (by invitation only)
16:30	Presentation of selected abstracts
Opening—Keynote Lectures Chairs: Mario Dicato, MD and Eric Van Cutsem, MD, PhD
17:00	Jacques Wils honorary lecture: Molecular changes during colorectal carcinogenesis Speaker invited
17:30	Keynote lecture: Genomic profiling of colorectal cancer and implications for treatment David J. Kerr, CBE, MD, FRCP
18:00	Keynote lecture: Prevention of upper gastrointestinal cancer Speaker invited

Thursday, 17 June 2004
8:00	Meet the professor sessions
	• Biliary tract cancer: Manfred P. Lutz, MD
	• Anal cancer: Jean-François Bosset, MD
	• Neuroendocrine tumors of the GI tract: Bertram Wiedenmann, MD
	• Locoregional treatment of liver metastases: Dominique Elias, MD
	• Gastrointestinal lymphoma: Speaker invited

Session I: Esophageal and gastric cancer Chairs: Karin Haustermans, MD, PhD and John S. Macdonald, MD
	Controversy Topic 1: Chemoradiotherapy in esophageal cancer
	9:00	The role of chemoradiotherapy in esophageal cancer Hans-Jochen Wilke, MD
	9:30	Discussion: Chemoradiotherapy versus surgery or chemoradiotherapy in addition to surgery Chair: Philippe Rougier, MD Panel: Robert Glynne-Jones, MD, Toni Lerut, MD and Hans-Jochen Wilke, MD
10:00	Chemotherapy for advanced gastric cancer Eric Van Cutsem, MD, PhD
10:20	The role of novel targets in esophageal and gastric cancer Josep Tabernero, MD
10:40	Break
	Controversy Topic 2: Which neoadjuvant or adjuvant treatment is appropriate for gastric cancer?
	11:10	Surgery for gastric cancer: Extensive or limited? Cornelis J.H. van de Velde, MD, PhD
	11:25	Postoperative chemoradiotherapy for gastric cancer John S. Macdonald, MD
	11:40	Preoperative chemotherapy for gastric cancer David Cunningham, MD
	11:55	Discussion: What is the optimal strategy for high-risk resectable gastric cancer? Chair: Arnaud D. Roth, MD Panel: David Cunningham, MD, Yoon-Koo Kang, MD, PhD, John S. Macdonald, MD and Cornelis J.H. van de Velde, MD, PhD
12:30	Concurrent lunch symposia Lunch symposium A: Supported by Sanofi-Synthelabo Lunch symposium B: TBA

Session II: Cancer of the liver and pancreas Chairs: David Cunningham, MD and Roberto Labianca, MD
14:00	The treatment of hepatocellular carcinoma Jordi Bruix, MD
14:20	Molecular markers in pancreatic cancer: Implications for treatment James L. Abbruzzese, MD
14:40	Which staging methods influence the approach to patients with pancreatic cancer and bile duct cancer? Dirk J. Gouma, MD
15:00	Surgery for pancreatic cancer and biliary tract cancer Valerio Di Carlo, MD
15:20	Break
	Controversy Topic 3: Adjuvant and neoadjuvant treatment for pancreatic cancer
	15:50	The European perspective Jean-Luc Van Laethem, MD, PhD
	16:05	The US perspective Margaret A. Tempero, MD
	16:20	Discussion: What is the optimal neo- or adjuvant treatment in pancreatic cancer? Chair: Karin Haustermans, MD, PhD Panel: James L. Abbruzzese, MD, Valerio Di Carlo, MD, Margaret Tempero, MD and Jean-Luc Van Laethem, MD, PhD
16:50	The management of locally advanced pancreatic cancer Michel Ducreux, MD, PhD
17:10	The management of metastatic pancreatic cancer: Current options and future developments James L. Abbruzzese, MD
17:45	Satellite symposium Supported by Merck KGaA

Friday, 18 June 2004
8:00	Meet the professor sessions
	• Biliary tract cancer: Manfred P. Lutz, MD
	• Anal cancer: Jean-François Bosset, MD
	• Neuroendocrine tumors of the GI tract: Bertram Wiedenmann, MD
	• Locoregional treatment of liver metastases: Dominique Elias, MD
	• Gastrointestinal lymphoma: Speaker invited

Session III: Colorectal cancer: Prevention and screening Chairs: Nadir Arber, MD and Patrick G. Johnston, MD, PhD
9:00	Prevention and screening for colorectal cancer Wendy P. Atkin, MPH, PhD
9:20	Chemoprevention for colorectal cancer Nadir Arber, MD
9:40	Hereditary and familial colon cancer Sabine Tejpar, MD, PhD
10:00	Controversial cases Nadir Arber, MD, Wendy P. Atkin, MPH, MD and Sabine Tejpar, MD, PhD
10:15	Break

Session IV: Colorectal cancer: Imaging and staging Chairs: Eduardo Díaz-Rubio, MD and Bengt Glimelius, MD
10:40	Virtual endoscopy for colon cancer Andrea Laghi, MD
11:00	Imaging for liver metastases Speaker invited
11:20	Role of PET scan in colorectal cancer Patrick Flamen, MD, PhD
11:40	Endoscopic ultrasound in rectal cancer: The impact on treatment and outcome Marc Giovannini, MD
12:00	Role of MRI in rectal cancer Regina Beets-Tan, MD, PhD
12:30	Concurrent lunch symposia Lunch symposium C: Supported by Aventis Lunch symposium D: Supported by Eli Lilly and Company

Session V: Surgery for colorectal cancer Chairs: Bernard Nordlinger, MD and Werner Scheithauer, MD
14:00	Laparoscopic surgery for colon and rectal cancer Speaker invited
14:20	Surgery for peritoneal metastases and pseudomyxoma peritonei Dominique Elias, MD
	Controversy Topic 4: Resection or ablation of liver metastases
	14:40	Debate: Bernard Nordlinger, MD (pro surgery) versus Thierry de Baère, MD (pro radiofrequency)
	15:05	Presentation of selected abstracts or cases Mario Dicato, MD
15:20	Break

Session VI: Multimodality therapy for rectal cancer Chairs: Bruce D. Minsky, MD and Arnaud D. Roth, MD
15:50	Adequate surgical resection for rectal cancer The surgeon’s view: Lars Pahlman, MD, PhD The pathologist’s view: Speaker invited
16:20	The approach to small rectal tumors David Sebag-Montefiore, MD
	Controversy Topic 5: Optimal (neo)adjuvant treatment for rectal cancer
	16:40	Preoperative short course radiotherapy Bengt Glimelius, MD
	16:50	Preoperative long course chemoradiotherapy regimen Vicenzo Valentini, MD
	17:00	The US view Joel E. Tepper, MD
	17:10	Discussion of controversial cases Chair: Bengt Glimelius, MD Panel: Daniel G. Haller, MD, Bruce D. Minsky, MD, Joel E. Tepper, MD, Vicenzo Valentini, MD and Lars Pahlman, MD, PhD
17:30	Satellite symposium Sponsored by F. Hoffmann-La Roche

Saturday, 19 June 2004
Session VII: Gastrointestinal stromal tumors (GIST) Chair: Mario Dicato, MD and John R. Zalcberg, MD
9:00	Molecular events in GIST Markku Miettinen, MD, PhD
9:20	The management of GIST Charles D. Blanke, MD
9:40	Is a PET scan a necessary tool in the treatment of GIST? Sigrid Stroobandts, MD, PhD
9:50	What to do in case of resistance to imatinib? Charles D. Blanke, MD
10:00	Break

Session VIII: Adjuvant therapy for colon cancer Chairs: Aimery de Gramont, MD and Hans-Joachim Schmoll, MD, PhD
10:30	The adjuvant treatment of stage III colon cancer Daniel G. Haller, MD
10:50	The role of prognostic markers and their impact on the adjuvant treatment of colorectal cancer Mario Dicato, MD
	Controversy Topic 6: The management of stage II colon cancer
	11:10	Panel Discussion Chair: Al B. Benson III, MD Panel: Stefano Cascinu, MD, David Cunningham, MD, Daniel G. Haller, MD, Bernard Nordlinger, MD, Werner Scheithauer, MD, John R. Zalcberg, MD
11:40	Hot topics from ASCO or presentation of selected abstracts
12:00	Lunch symposium Supported by F. Hoffmann-La Roche

Session IX: Metastatic colorectal cancer Chairs: Daniel G. Haller, MD and Eric Van Cutsem, MD, PhD
13:30	How do I treat a patient with metastatic colorectal cancer in first and second line in the USA in 2004? Richard M. Goldberg, MD
13:45	How do I treat a patient with metastatic colorectal cancer in first and second line in Europe in 2004? Philippe Rougier, MD
14:00	The role of novel targeted agents in colorectal cancer Eric Van Cutsem, MD, PhD
14:20	Predictive molecular markers and their impact on the choice of treatment Patrick G. Johnston, MD, PhD
14:40	What is the optimal duration of treatment in metastatic colorectal cancer? Paulo M. Hoff, MD
14:55	The chemotherapy for elderly patients with metastatic colorectal cancer Speaker invited
	Controversy Topic 7: Optimal treatment in poor risk patients
	15:10	Panel Discussion Chair: Claus-Henning Köhne, MD, PhD Panel: Al B. Benson III, MD, Richard M. Goldberg, MD, Philippe Rougier, MD and Hans-Joachim Schmoll, MD
15:30	Presentation of expert discussion on surveillance and follow-up of colon cancer Eric Van Cutsem, MD, PhD
16:00	Adjourn

C O N T I N U I N G M E D I C A L E D U C A T I O N

This program will be submitted to ESMO for accreditation. Participants will receive a certificate of attendance at the end of the congress.

G E N E R A L I N F O R M A T I O N

The congress language is English without translation.

For more information about Barcelona, please visit www.barcelonaturisme.com or www.bcn.es

The Registration and Information Desk will be staffed:
Wednesday, 16 . . . . . . . June 12:00 – 20:00
Thursday, 17 . . . . . . . . . June 7:00 – 19:00
Friday, 18 . . . . . . . . . . . . June 7:00 – 19:00
Saturday, 19 . . . . . . . . . . June 8:00 – 16:30

Conference Location
Palau de Congresos de Catalunya
Av. Diagonal, 661-671
08028 Barcelona, Spain
Tel.: +34 93 364 44 00
Fax: +34 93 364 44 01

O R G A N I Z E R

          70 Technology Drive
          Alpharetta, GA 30005-3969 USA
          Tel.: +1 (770) 751 7332
          Fax: +1 (770) 751 7334
          Email: meetings@imedex.com
          Web: www.imedex.com